OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Deol on the Curative Potential of CAR T-Cell Therapy in ALL

October 8th 2020

Abhinav Deol, MD, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia.

Dr. Pemmaraju on the Potential Role of Novel Therapies in MPNs

October 8th 2020

Naveen Pemmaraju, MD, discusses the potential role of novel therapies in myeloproliferative neoplasms.

Dr. Yap on the Rationale for the SEASTAR Trial in Advanced Solid Tumors

October 8th 2020

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for the ongoing phase 1b/2 SEASTAR trial in advanced solid tumors.

Dr. Pleyer on Next Steps With Ibrutinib Plus Short-Course Fludarabine in Previously Untreated CLL

October 8th 2020

Christopher Pleyer, MD, discusses the next steps with the combination of ibrutinib and short-course fludarabine in previously untreated chronic lymphocytic leukemia.

Dr. Maki on the Evolving Treatment Landscape in Soft Tissue Sarcoma

October 8th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the evolving treatment landscape of soft tissue sarcoma.

Dr. Kantoff on the Need to Develop New Therapies in mCRPC

October 8th 2020

Philip W. Kantoff, MD, discusses the need to develop new therapies in metastatic castration-resistant prostate cancer.

Dr. Pleyer on Remaining Questions With Ibrutinib Plus Short-Course Fludarabine in CLL

October 8th 2020

Christopher Pleyer, MD, discusses the safety and effectiveness of ibrutinib plus short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Dr. Lin on Treatment Challenges in HER2+ Breast Cancer and Brain Metastases

October 8th 2020

Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.

Dr. Burris on the Exploration of PARP Inhibitors in TNBC

October 8th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.

Dr. Concin on the Rationale for the LIO-1 Trial in Advanced Gynecologic Malignancies

October 7th 2020

Nicole Concin, MD, discusses the rationale for the phase 1/2 LIO-1 trial in advanced gynecologic malignancies.

Dr. Shoushtari on the Rationale for the CheckMate-067 Trial in Advanced Melanoma

October 7th 2020

Alexander N. Shoushtari, discusses the rationale for the phase 3 CheckMate-067 trial in advanced melanoma.

Dr. Paplomata on the Clinical Impact of Tucatinib in HER2+ Breast Cancer

October 7th 2020

Elisavet Paplomata, MD, discusses the clinical impact of tucatinib in HER2-positive breast cancer.

Dr. Petrylak on the Utility of Tissue Versus Liquid Biopsy in Prostate Cancer

October 7th 2020

Daniel P. Petrylak, MD, discusses the utility of tissue biopsy versus liquid biopsy in prostate cancer.

Dr. Doroshow on the Impact of the COVID-19 Pandemic on Cancer Care

October 7th 2020

Deborah B. Doroshow, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on cancer care.

Dr. Seymour on the Efficacy Ibrutinib Versus Chemoimmunotherapy in Older Patients With CLL

October 7th 2020

Erlene Seymour, MD, discusses the use of ibrutinib versus chemoimmunotherapy in older patients with untreated chronic lymphocytic leukemia.

Dr. Deol on the Utility of Tisagenlecleucel in ALL

October 7th 2020

Abhinav Deol, MD, discusses the approval of the CAR T-cell therapy tisagenlecleucel for pediatric patients with acute lymphoblastic leukemia.

Dr. Lonial Discusses Ongoing Research With BiTEs and CAR T-Cell Therapy in Myeloma

October 6th 2020

Sagar Lonial, MD, FACP, discusses the development of bispecific T-cell engagers (BiTEs) and CAR T-cell therapy in multiple myeloma.

Dr. Hamilton on the Exploration of CDK4/6 Inhibitors in Breast Cancer

October 6th 2020

Erika P. Hamilton, MD, discusses the exploration of CDK4/6 Inhibitors in HER2-positive breast cancer.

Dr. Davids on the Use of Chemoimmunotherapy in CLL

October 6th 2020

Matthew S. Davids, MD, MMSc, discusses the use of chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Dr. Hussain on the Need for Collaboration to Cure Prostate Cancer

October 6th 2020

Maha Hussain, MD, FACP, FASCO, discusses the need for collaboration to cure patients with prostate cancer.